3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
4
Prostatic Neoplasms
3
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumour
1
Recurrence
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
1
Healthy Participants
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Tumours
1
Advanced Solid Malignancy,
1
Advanced Solid Malignancy
1
Advanced Gastric Cancer
1
Advanced Cancer
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
67
Dexamethasone
52
Peripheral Blood Stem Cell Transplantation
37
Lenalidomide
37
Rituximab
35
fludarabine phosphate
34
Bortezomib
30
Filgrastim
27
Etoposide
27
Cytarabine
25
Carboplatin
25
Busulfan
23
Radiotherapy
22
Melphalan
22
Gemcitabine
22
Cyclosporine
21
pomalidomide
20
fludarabine
20
Whole-Body Irradiation
20
Mycophenolic Acid
20
Paclitaxel
19
Methotrexate
18
venetoclax
17
Cisplatin
17
pembrolizumab
16
Calcium Dobesilate
16
Bevacizumab
16
Tacrolimus
14
Antilymphocyte Serum
14
Nivolumab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Recurrence
×
capivasertib
×
Clear all
NCT05008055
2024-12-20
CAPITAL
AstraZeneca
Phase 2
Completed
30 enrolled
15 charts